Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Medicenna Therapeutics Reports Regulatory Clearance To Expand Phase 1/2 ABILITY Study Of MDNA11 To Canada
-- ABILITY Study is currently ongoing at clinical trial sites in Australia and previously received FDA clearance to expand to sites in the United States
-- Preliminary update on safety and PK/PD data expected by
Medicenna Therapeutics Shares Rise In Price On Low Volume; Traders Circulate Seeking Alpha Blog Post From Contributor BioSci Capital Partners’s Blog Titled ‘IBI Research On Medicenna: A Platform Technology Innovator To Decimate Cancers’
https://seekingalpha.com/instablog/17806842-biosci-capital-partners/5672758-ibi-research-on-medicenna-platform-technology-innovator-to-decimate-cancers
80 Biggest Movers From Yesterday
Gainers
BIMI International Medical Inc. (NASDAQ: BIMI) shares surged 55% to close at $1.00 on Tuesday as the company reported a narrower Q3 loss.
53 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
BIMI International Medical Inc. (NASDAQ: BIMI) jumped 65.7% to $1.0691 as the company reported a narrower Q3 loss.
Earnings Scheduled For November 12, 2021
Companies Reporting Before The Bell
• Zevia (NYSE:ZVIA) is estimated to report quarterly loss at $0.43 per share on revenue of $34.40 million.
Medicenna Therapeutics Reports FDA Clearance Of Investigational New Drug Application To Expand Phase 1/2 ABILITY Study Of MDNA11 To US
-- ABILITY Study is currently ongoing at clinical trial sites in Australia
-- Preliminary update on safety, PK/PD, and biomarker data expected by year-end 2021
-- Initial efficacy data update expected in
Medicenna Announces Issuance Of U.S. Patent Providing Added Intellectual Property Protection For Its MDNA11 Program
Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced that the US Patent and Trademark Office (USPTO) has
Medicenna Doses First Patient In MDNA11 Phase 1/2 ABILITY Study
-- Trial designed to assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of MDNA11 in patients with advanced solid tumors
-- Preliminary update on safety, PK/PD, and biomarker
MDNA: On Track to Dose First Patient in MDNA11 Phase 1 Trial in 3Q21…
By David Bautz, PhD
NASDAQ:MDNA
READ THE FULL MDNA RESEARCH REPORT